Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates
ApconiX is a team of world-renowned nonclinical safety experts with over 500 years of drug discovery and development expertise. We will work with you to provide the advice you need, at the right time to make better decisions on drug safety, from project initiation through to worldwide marketing approval. ApconiX has a team of experienced scientists covering all major safety disciplines, our own ion channel laboratory and a commitment to advancing the science of drug safety.
